Dexmedetomidine-esketamine
Phase 3Small molecule
Dexmedetomidine-esketamine is one of 6 small molecule programs targeting Sedation. It is currently in Phase 3.
3
Indications
7
Total Trials
3
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Postoperative Quality of Recovery
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Spravato
WWim Janssens
Approved
Dexmedetomidine-esketamine
PPeking University First Hospital
Phase 3
Imitrex
GGlaxo Dba Glaxosmithkline
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Ciprofol
Haisco Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dexmedetomidine2 trials
Postoperative Quality of Recovery1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexmedetomidine-esketamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University First Hospital